PK of Telmisartan and Amlodipine in Healthy Volunteers

Phase 1, randomised, open-label trial of telmisartan in hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of telmisartan in plasma at steady state over a uniform dosing interval tau up to 15 days and Maximum measured concentration of telmisartan in plasma at steady state up to 15 days. Started May 2006; status: completed.